X4 Pharmaceuticals reported total revenue of $14.4 million for the first nine months of 2026, a decrease from $32.5 million in the prior year period, primarily due to lower license revenue. Net product revenue from XOLREMDI grew to $7.6 million year-to-date, while the company reduced its nine-month operating loss to $56.7 million through significant cuts in research, development, and administrative expenses.
X4 Pharmaceuticals is hosting a Virtual Investor Day on October 29, 2026, to provide updates on its strategic business plans and clinical pipeline. The presentation focuses on the commercialization of mavorixafor for primary chronic neutropenia and the progress of the ongoing 4WARD Phase 3 clinical study.
X4 Pharmaceuticals Executive Chairman Adam R. Craig Buys $11.9K of Stock
Adam R. Craig, Executive Chairman, bought 4,600 shares of X4 Pharmaceuticals, Inc at $2.58 a share, worth $11.9K in total on Oct 16, 2026. Shares held after the trade: 333,251 (+1.4%).
X4 Pharmaceuticals $150M Debt Financing with K2 HealthVentures LLC
X4 Pharmaceuticals entered into a $150 million senior secured term loan facility with K2 HealthVentures, consisting of an immediate $80 million tranche and an additional $70 million available upon request and lender approval. The proceeds were used to repay an existing $75 million loan from Hercules and will support the potential commercial launch of mavorixafor. The new facility features a 48-month maturity and an interest-only period through at least October 2029.
X4 Pharmaceuticals CFO David Kirske Sells $33.7K of Stock
David Kirske, CFO, sold 11,767 shares of X4 Pharmaceuticals, Inc at $2.86 a share, worth $33.7K in total on Oct 1, 2026. Shares held after the trade: 155,983 (-7.0%).